JAML

Summary

JAML (junction adhesion molecule like, HGNC:19084) is a protein-coding gene on chromosome 11q23.3, encoding Junctional adhesion molecule-like (Q86YT9). Transmembrane protein of the plasma membrane of leukocytes that control their migration and activation through interaction with CXADR, a plasma membrane receptor found on adjacent epithelial and endothelial cells.

Enables integrin binding activity and protein homodimerization activity. Involved in heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules and myeloid leukocyte migration. Located in bicellular tight junction; nucleoplasm; and plasma membrane.

Source: NCBI Gene 120425 — RefSeq curated summary.

At a glance

• GWAS associations: 16
• Clinical variants (ClinVar): 15 total
• MANE Select transcript: NM_001098526

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19084
Approved symbol	JAML
Name	junction adhesion molecule like
Location	11q23.3
Locus type	gene with protein product
Status	Approved
Aliases	Gm638, AMICA
Ensembl gene	ENSG00000160593
Ensembl biotype	protein_coding
OMIM	609770
Entrez	120425

Gene structure

Transcript identifiers

Ensembl transcripts: 26 — 20 protein_coding, 4 retained_intron, 2 nonsense_mediated_decay

ENST00000292067, ENST00000356289, ENST00000524477, ENST00000525565, ENST00000526595, ENST00000526620, ENST00000527877, ENST00000529164, ENST00000531530, ENST00000531536, ENST00000533261, ENST00000534294, ENST00000911163, ENST00000911164, ENST00000911165, ENST00000911166, ENST00000911167, ENST00000911168, ENST00000911169, ENST00000911170, ENST00000911171, ENST00000946619, ENST00000946620, ENST00000946621, ENST00000946622, ENST00000946623

RefSeq mRNA: 4 — MANE Select: NM_001098526 NM_001098526, NM_001286570, NM_001286571, NM_153206

CCDS: CCDS41723, CCDS66240, CCDS8391

Canonical transcript exons

ENST00000356289 — 10 exons

Exon	Start	End
ENSE00001557461	118193725	118194417
ENSE00002201958	118224941	118225011
ENSE00003467515	118197998	118198091
ENSE00003491829	118196735	118196821
ENSE00003495462	118205882	118205991
ENSE00003503629	118214824	118214886
ENSE00003507881	118212407	118212561
ENSE00003560789	118210487	118210712
ENSE00003644396	118200474	118200612
ENSE00003676943	118203428	118203665

Expression profiles

Bgee: expression breadth ubiquitous, 215 present calls, max score 99.48.

FANTOM5 (CAGE): breadth broad, TPM avg 15.4591 / max 1332.8583, expressed in 382 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
122583	11.2672	352
122584	2.5165	246
122585	1.4457	186
122577	0.1442	31
122582	0.0487	18
122576	0.0240	8
122575	0.0130	1

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	99.48	gold quality
leukocyte	CL:0000738	99.47	gold quality
granulocyte	CL:0000094	99.31	gold quality
blood	UBERON:0000178	99.02	gold quality
vermiform appendix	UBERON:0001154	98.39	gold quality
spleen	UBERON:0002106	95.97	gold quality
right lung	UBERON:0002167	94.05	gold quality
caecum	UBERON:0001153	93.98	gold quality
lymph node	UBERON:0000029	93.69	gold quality
gall bladder	UBERON:0002110	93.52	gold quality
bone marrow	UBERON:0002371	92.74	gold quality
rectum	UBERON:0001052	92.55	gold quality
bone marrow cell	CL:0002092	91.52	gold quality
upper lobe of left lung	UBERON:0008952	91.10	gold quality
trabecular bone tissue	UBERON:0002483	90.61	gold quality
upper lobe of lung	UBERON:0008948	90.40	gold quality
bone element	UBERON:0001474	90.12	gold quality
small intestine Peyer’s patch	UBERON:0003454	89.95	gold quality
small intestine	UBERON:0002108	88.65	gold quality
mucosa of transverse colon	UBERON:0004991	87.59	gold quality
right coronary artery	UBERON:0001625	87.15	gold quality
amniotic fluid	UBERON:0000173	86.99	gold quality
lung	UBERON:0002048	86.94	gold quality
pancreatic ductal cell	CL:0002079	86.58	silver quality
smooth muscle tissue	UBERON:0001135	86.57	gold quality
duodenum	UBERON:0002114	86.03	gold quality
upper arm skin	UBERON:0004263	85.24	silver quality
colonic epithelium	UBERON:0000397	85.04	gold quality
lower lobe of lung	UBERON:0008949	84.98	silver quality
pylorus	UBERON:0001166	84.44	gold quality

Single-cell (SCXA)

Detected in 24 experiment(s), a significant marker in 21.

Experiment	Marker?	Max mean expression
E-MTAB-7381	yes	1538.10
E-CURD-97	yes	1143.78
E-CURD-88	yes	927.97
E-MTAB-8142	yes	908.43
E-HCAD-32	yes	714.98
E-MTAB-9067	yes	592.34
E-MTAB-6701	yes	467.20
E-HCAD-1	yes	70.93
E-HCAD-6	yes	41.87
E-HCAD-10	yes	36.05
E-CURD-46	yes	35.12
E-MTAB-10553	yes	32.48
E-HCAD-8	yes	29.46
E-MTAB-6678	yes	25.31
E-CURD-112	yes	25.16

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

18 targeting JAML, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-4328	99.57	71.06	4094
HSA-MIR-143-3P	99.49	69.05	1457
HSA-MIR-4770	99.49	69.09	1451
HSA-MIR-6731-5P	99.28	67.42	2375
HSA-MIR-8085	99.28	67.56	2362
HSA-MIR-3152-3P	99.10	66.35	678
HSA-MIR-455-5P	98.74	67.31	795
HSA-MIR-6840-3P	98.68	65.95	1923
HSA-MIR-7977	98.65	66.18	2590
HSA-MIR-4691-5P	98.41	66.77	1343
HSA-MIR-6792-3P	98.41	66.86	1359
HSA-MIR-653-3P	98.31	67.71	1542
HSA-MIR-6870-3P	98.08	65.10	692
HSA-MIR-3151-3P	97.80	66.16	479
HSA-MIR-4733-5P	97.75	67.44	866

Literature-anchored findings (GeneRIF, showing 10)

• expressed on leukocytes with a possible role in leukocyte transmigration (PMID:12869515)
• Integrin activation is required for the dissociation of JAM-L-VLA-4 complexes and the accumulation of functional JAM-L dimers, which indicates that the leukocyte integrin VLA-4 controls JAM-L function in cis by controlling its dimerization state. (PMID:19064666)
• Findings suggest that specific JAM family members play an important role in the transendothelial migration (TEM) of in vitro-generated mouse and human dendritic cells (DCs) from the inoculation site to regional lymph nodes (LNs) in DC-based cancer immunotherapy. (PMID:30055289)
• Elevation of JAML Promotes Diabetic Kidney Disease by Modulating Podocyte Lipid Metabolism. (PMID:33186558)
• JAML promotes CD8 and gammadelta T cell antitumor immunity and is a novel target for cancer immunotherapy. (PMID:34427588)
• Junctional Adhesion Molecule-Like Protein (JAML) Is Correlated with Prognosis and Immune Infiltrates in Lung Adenocarcinoma. (PMID:35034089)
• Junctional adhesion molecule-like protein promotes tumor progression via the Wnt/beta-catenin signaling pathway in lung adenocarcinoma. (PMID:35672776)
• Junctional adhesion molecule-like protein as a novel target for kaempferol to ameliorate lung adenocarcinoma. (PMID:37069006)
• JAML promotes the antitumor role of tumor-resident CD8[+] T cells by facilitating their innate-like function in human lung cancer. (PMID:38570084)
• JAML inhibits colorectal carcinogenesis by modulating the tumor immune microenvironment. (PMID:38625487)

Cross-species orthologs

0 orthologs

Paralogs (6): MPZL2 (ENSG00000149573), SCN2B (ENSG00000149575), MPZ (ENSG00000158887), MPZL3 (ENSG00000160588), SCN4B (ENSG00000177098), MPZL1 (ENSG00000197965)

Protein

Protein identifiers

Junctional adhesion molecule-like — Q86YT9 (reviewed: Q86YT9)

Alternative names: Adhesion molecule interacting with CXADR antigen 1, Dendritic cell-specific protein CREA7-1

All UniProt accessions (6): Q86YT9, E9PJJ4, E9PKK2, E9PLF9, E9PNS8, E9PR26

UniProt curated annotations — full annotation on UniProt →

Function. Transmembrane protein of the plasma membrane of leukocytes that control their migration and activation through interaction with CXADR, a plasma membrane receptor found on adjacent epithelial and endothelial cells. The interaction between both receptors mediates the activation of gamma-delta T-cells, a subpopulation of T-cells residing in epithelia and involved in tissue homeostasis and repair. Upon epithelial CXADR-binding, JAML induces downstream cell signaling events in gamma-delta T-cells through PI3-kinase and MAP kinases. It results in proliferation and production of cytokines and growth factors by T-cells that in turn stimulate epithelial tissues repair. It also controls the transmigration of leukocytes within epithelial and endothelial tissues through adhesive interactions with epithelial and endothelial CXADR.

Subunit / interactions. Homodimer; active form in leukocyte-endothelial cell adhesion. Interacts (homodimeric form) with CXADR. Interacts (via cytoplasmic domain) with the PI3 kinase; upon CXADR-binding. Interacts with ITGA4 and ITGB1; integrin alpha-4/beta-1 may regulate leukocyte to endothelial cells adhesion by controlling JAML homodimerization.

Subcellular location. Cell membrane. Cell junction.

Tissue specificity. Expression is restricted to the hematopoietic tissues with the exception of liver. Expressed in fetal liver, spleen and thymus. Preferentially expressed by mature leukocytes (at protein level).

Domain organisation. The Ig-like V-type domain 1 mediates interaction with CXADR. The Ig-like V-type domain 2 may also play a role in the interaction.

Induction. Up-regulated upon retinoic acid, Me2SO and PMA treatment in differentiating myeloid leukemia cells.

Similarity. Belongs to the immunoglobulin superfamily.

Isoforms (4)

UniProt ID	Names	Canonical?
Q86YT9-1	1	yes
Q86YT9-2	2
Q86YT9-3	3
Q86YT9-4	4

RefSeq proteins (4): NP_001091996, NP_001273499, NP_001273500, NP_694938 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000920	Myelin_P0-rel	Family
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013106	Ig_V-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily

Pfam: PF07686

UniProt features (22 total): splice variant 4, sequence variant 3, glycosylation site 2, disulfide bond 2, topological domain 2, domain 2, signal peptide 1, chain 1, mutagenesis site 1, sequence conflict 1, transmembrane region 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86YT9-F1	73.60	0.41

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (2): 42–116, 155–234

Glycosylation sites (2): 231, 76

Mutagenesis-validated functional residues (1):

Position	Phenotype
54	loss of the ability to homodimerize, loss of interaction with cxadr and loss of function in cell-cell adhesion.

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-198933	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-202733	Cell surface interactions at the vascular wall
R-HSA-109582	Hemostasis
R-HSA-1280218	Adaptive Immune System
R-HSA-168256	Immune System

MSigDB gene sets: 156 (showing top): GOBP_HETEROPHILIC_CELL_CELL_ADHESION, GOBP_MYELOID_LEUKOCYTE_MIGRATION, GOBP_CELL_CHEMOTAXIS, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOBP_LEUKOCYTE_CHEMOTAXIS, GOBP_WOUND_HEALING, GOBP_CELL_CELL_ADHESION, GOBP_TAXIS, GOBP_CELLULAR_EXTRAVASATION, GOBP_LEUKOCYTE_MIGRATION, WANG_LMO4_TARGETS_DN, CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP, ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN, GOBP_GRANULOCYTE_MIGRATION, RYTTCCTG_ETS2_B

GO Biological Process (8): heterophilic cell-cell adhesion (GO:0007157), neutrophil chemotaxis (GO:0030593), monocyte extravasation (GO:0035696), gamma-delta T cell activation (GO:0046629), positive regulation of epithelial cell proliferation involved in wound healing (GO:0060054), neutrophil extravasation (GO:0072672), immune system process (GO:0002376), cell adhesion (GO:0007155)

GO Molecular Function (4): integrin binding (GO:0005178), protein homodimerization activity (GO:0042803), cell adhesion molecule binding (GO:0050839), protein binding (GO:0005515)

GO Cellular Component (5): nucleoplasm (GO:0005654), plasma membrane (GO:0005886), bicellular tight junction (GO:0005923), membrane (GO:0016020), anchoring junction (GO:0070161)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Adaptive Immune System	1
Hemostasis	1
Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
neutrophil migration	2
cellular extravasation	2
cellular anatomical structure	2
cell-cell adhesion	1
granulocyte chemotaxis	1
mononuclear cell migration	1
myeloid leukocyte migration	1
T cell activation	1
wound healing	1
positive regulation of epithelial cell proliferation	1
biological_process	1
cellular process	1
signaling receptor binding	1
protein-containing complex binding	1
cell adhesion molecule binding	1
identical protein binding	1
protein dimerization activity	1
protein binding	1
binding	1
nuclear lumen	1
membrane	1
cell periphery	1
apical junction complex	1
tight junction	1
cell junction	1

Protein interactions and networks

STRING

1096 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
JAML	CXADR	P78310	902
JAML	PLXNB2	O15031	815
JAML	CD28	P10747	716
JAML	IGSF5	Q9NSI5	671
JAML	JAM2	P57087	588
JAML	JAM3	Q9BX67	585
JAML	F11R	Q9Y624	553
JAML	ESAM	Q96AP7	477
JAML	IL17A	Q16552	455
JAML	SEMA4D	Q92854	446
JAML	RCVRN	P35243	423
JAML	REG3G	Q6UW15	423
JAML	GAPT	Q8N292	423
JAML	IGF1	P01343	406
JAML	CD79B	P40259	392

IntAct

9 interactions, top by confidence:

A	B	Type	Score
JAML	CXADR	psi-mi:“MI:0915”(physical association)	0.590
CXADR	JAML	psi-mi:“MI:0915”(physical association)	0.590
CD320	JAML	psi-mi:“MI:0407”(direct interaction)	0.520
JAML	CD320	psi-mi:“MI:0403”(colocalization)	0.520
BTN1A1	JAML	psi-mi:“MI:0915”(physical association)	0.400
	JAML	psi-mi:“MI:0915”(physical association)	0.000
JAML	yscP	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (3): MAL (Two-hybrid), AMICA1 (Affinity Capture-MS), AMICA1 (Reconstituted Complex)

ESM2 similar proteins: A6QQC6, A8MVW5, B0CLX4, O88775, O95976, P01730, P01731, P01881, P01882, P05540, P06332, P06729, P08920, P08921, P10252, P16003, P16004, P18181, P20746, P21995, P37998, P42071, P42082, P43432, P79184, P79185, Q07763, Q08338, Q08340, Q28938, Q29037, Q29RR6, Q3MHP9, Q3T113, Q4KLY3, Q4VAH7, Q6GMZ9, Q6PCB8, Q6SZ61, Q6UXZ0

Diamond homologs: A0JM41, A2VD98, A5D7C3, O60487, O60939, O70255, O95297, P06907, P10522, P20938, P25189, P27573, P37301, P54900, P78310, P97792, Q08E08, Q32PI9, Q3TEW6, Q3V3F6, Q4KLY3, Q56A07, Q5EAB0, Q5R764, Q5R804, Q6AYT8, Q6UWV2, Q6WEB5, Q864L3, Q86YT9, Q8AVM3, Q8IWT1, Q8WMV3, Q91664, Q96IQ7, Q9PWR4, Q9R066, Q7M730, Q2KI11, Q7M729

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

15 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	5
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1960 predictions. Top by Δscore:

Variant	Effect	Δscore
11:118197970:A:AC	donor_gain	1.0000
11:118197971:G:C	donor_gain	1.0000
11:118198001:C:A	donor_gain	1.0000
11:118203408:C:A	donor_gain	1.0000
11:118203426:A:AC	donor_gain	1.0000
11:118203427:C:CC	donor_gain	1.0000
11:118203429:T:TA	donor_gain	1.0000
11:118203439:T:TA	donor_gain	1.0000
11:118203524:C:CA	donor_gain	1.0000
11:118203529:ACT:A	donor_gain	1.0000
11:118203530:CTC:C	donor_gain	1.0000
11:118203532:C:CA	donor_gain	1.0000
11:118195057:G:C	donor_gain	0.9900
11:118195263:G:C	donor_gain	0.9900
11:118196822:C:CC	acceptor_gain	0.9900
11:118197999:T:TA	donor_gain	0.9900
11:118198000:C:A	donor_gain	0.9900
11:118203495:A:AC	donor_gain	0.9900
11:118203496:C:CC	donor_gain	0.9900
11:118210482:CGTA:C	donor_loss	0.9900
11:118210483:GTA:G	donor_loss	0.9900
11:118210484:TA:T	donor_loss	0.9900
11:118210485:A:C	donor_loss	0.9900
11:118210517:C:CT	donor_gain	0.9900
11:118210529:TGAAC:T	donor_gain	0.9900
11:118212401:CGTTA:C	donor_loss	0.9900
11:118212402:GTTA:G	donor_loss	0.9900
11:118212403:TTAC:T	donor_loss	0.9900
11:118212404:TACCT:T	donor_loss	0.9900
11:118212405:A:C	donor_loss	0.9900

AlphaMissense

2574 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:118212436:A:G	W57R	0.991
11:118212436:A:T	W57R	0.991
11:118212434:C:A	W57C	0.988
11:118212434:C:G	W57C	0.988
11:118210571:A:C	Y114D	0.987
11:118205908:A:G	W170R	0.986
11:118205908:A:T	W170R	0.986
11:118210659:G:C	F84L	0.985
11:118210659:G:T	F84L	0.985
11:118210661:A:G	F84L	0.985
11:118210651:C:G	R87P	0.984
11:118210564:C:T	C116Y	0.978
11:118210564:C:G	C116S	0.976
11:118210565:A:G	C116R	0.976
11:118210565:A:T	C116S	0.976
11:118205906:C:A	W170C	0.975
11:118205906:C:G	W170C	0.975
11:118203506:A:C	Y232D	0.973
11:118210563:A:C	C116W	0.973
11:118212435:C:G	W57S	0.971
11:118210613:A:G	S100P	0.968
11:118210609:A:G	L101P	0.967
11:118200538:A:G	C283R	0.966
11:118203499:C:G	C234S	0.966
11:118203500:A:T	C234S	0.966
11:118210652:G:T	R87S	0.966
11:118210603:A:G	L103P	0.963
11:118210699:A:G	L71P	0.963
11:118210609:A:T	L101H	0.962
11:118203500:A:G	C234R	0.958

dbSNP variants (sampled 300 via entrez): RS1000033150 (11:118213787 C>T), RS1000104794 (11:118214136 C>T), RS1000145497 (11:118221245 T>C), RS1000352345 (11:118217503 C>T), RS1000390697 (11:118220607 C>T), RS1000404581 (11:118217207 A>G), RS1000598554 (11:118210928 A>G), RS1000616177 (11:118204040 CA>C,CAA), RS1000654480 (11:118197199 T>C), RS1000668434 (11:118203685 A>C,G), RS1000819846 (11:118224289 G>A), RS1000855349 (11:118206276 T>C), RS1000906521 (11:118193743 T>C), RS1000965041 (11:118206998 C>T), RS1001005304 (11:118197406 AAGAAT>A)

Disease associations

OMIM: gene MIM:609770 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

16 associations (top):

Study	Trait	p-value
GCST004610_123	White blood cell count	8.000000e-18
GCST004613_20	Sum neutrophil eosinophil counts	1.000000e-14
GCST004614_4	Granulocyte count	9.000000e-15
GCST004620_118	Sum basophil neutrophil counts	4.000000e-14
GCST004625_113	Monocyte count	4.000000e-09
GCST004626_113	Myeloid white cell count	6.000000e-16
GCST004629_99	Neutrophil count	6.000000e-14
GCST006585_417	Blood protein levels	0.000000e+00
GCST007560_2	Sleep duration (long sleep)	5.000000e-12
GCST90002393_444	Monocyte count	5.000000e-13
GCST90002398_130	Neutrophil count	6.000000e-16
GCST90002398_203	Neutrophil count	8.000000e-10
GCST90002398_204	Neutrophil count	2.000000e-32
GCST90002399_69	Neutrophil percentage of white cells	3.000000e-10
GCST90002407_339	White blood cell count	4.000000e-35
GCST90002407_340	White blood cell count	5.000000e-13

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004833	neutrophil count
EFO:0004842	eosinophil count
EFO:0007987	granulocyte count
EFO:0005090	basophil count
EFO:0005091	monocyte count
EFO:0007990	neutrophil percentage of leukocytes

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases expression	2
Nickel	decreases expression, increases expression	2
Cyclosporine	decreases expression	2
Aflatoxin B1	decreases expression, increases methylation	2
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
bisphenol A	decreases methylation	1
quercitrin	increases expression	1
butyraldehyde	increases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
gardiquimod	decreases expression, decreases reaction	1
(+)-JQ1 compound	decreases expression	1
Leflunomide	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Air Pollutants, Occupational	decreases expression	1
Cadmium	decreases expression	1
Cisplatin	increases expression	1
Hydrogen Peroxide	affects expression	1
Ozone	affects expression, increases abundance	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	increases expression	1
Valproic Acid	decreases expression	1
Antirheumatic Agents	decreases expression	1
Okadaic Acid	increases expression	1
Vitamin K 3	affects expression	1
Protein Kinase Inhibitors	decreases expression, decreases reaction	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.